Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.

NCT05297240 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT05297240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05297240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
Lead sponsor
PETHEMA Foundation
Phase
Observational
Overall status
Unknown status
Start date
March 24, 2022
Completion date
December 31, 2022
Enrollment
170 (estimated)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or refractory multiple myeloma